FDA Approves First In-Ear EEG Device, Expanding Real-World Brain Monitoring Beyond the Clinic

The FDA has approved Naox Link, an in-ear electroencephalographic (EEG) device (Naox Technologies), marking a significant shift in how clinicians can monitor brain activity outside of usual clinical environments.

Naox Technologies announced that its Naox Link system has received FDA 510(k) clearance, making it the first ear-worn EEG device authorized for clinical use in the United States.¹ The technology is set to have a significant impact not only in the field of neurologic diagnostics but also on the role of pharmacists in the administration of complex neurologic therapies.

EEG continues to be an essential diagnostic tool in the assessment of epilepsy, sleep disorders, encephalopathies, and other neurologic abnormalities. However, EEG systems rely on scalp electrodes and conductive gels that may not capture intermittent or context-dependent brain activity. According to Naox, these limitations have long constrained clinicians’ ability to observe how the brain functions during daily life. “EEG readings have traditionally been constrained by short recording windows, uncomfortable headgear, and clinical settings that fail to reflect patients’ real lives,” said Hugo Dinh, cofounder and CEO of Naox Technologies, in a company release.¹

The newly cleared Naox Link device addresses these barriers by shifting EEG acquisition from bulky scalp electrodes to a discreet, comfortable in-ear form factor. The system is designed to be worn for extended periods, including overnight, enabling longer, more frequent recordings in natural settings. “With FDA clearance of Naox Link, clinicians can extend EEG into everyday environments, enabling longer, repeated, more natural recordings and opening new possibilities for understanding brain activity beyond the clinic,” Dinh said.¹ The company added that “by moving EEG acquisition from bulky scalp electrodes and gel-based setups to a comfortable in-ear format, Naox Link enables clinicians to capture brain activity during everyday life, sleep, daily routines, and real-world conditions that are often missed during traditional 20-30 minute in-clinic EEG sessions.”¹

Specialists say this could seriously stretch the notion of how neurologic diseases are assessed and treated. Inpatient-based EEG works fine for a diagnosis but often fails to capture long-term brain dynamics, especially in chronic or episodic conditions.² Gilles Huberfeld, MD, PhD, a neurologist at the Rothschild Foundation Hospital in Paris, France, and adviser to Naox, emphasized this gap. “Hospital EEG is mainly efficient for disease diagnosis,” Huberfeld said in a statement.² “A comfortable in-ear system that works overnight and at home opens an entirely new window into brain function, one that may improve detection, monitoring, and understanding of neurological conditions.”¹ He added, “To be one step ahead of disease is a fantasy in medicine, even more so in neurology, and capturing the brain’s long-term dynamics is the first prerequisite.”²

For pharmacists, having access to real-world EEG data may assist with a more tailored approach to medication use, especially in patients on antiepileptic, sedative, sleeping, or other medications with known neurologic adverse effects. Many patients also deal with their symptoms in between clinic visits, such as intermittent seizures, sleep seizures, or cognitive effects from other medications, and having a longer EEG may assist in linking these symptoms with medication use and interactions in a more precise manner.³

The FDA clearance of Naox Link signals a broader shift toward a more decentralized, patient-centric approach to diagnosis, particularly in neurology. This is because the progression of the diseases and the response to the treatment will be done over a longer period. Pharmacists will play an important role in using wearable neurotech to translate the influx of neurologic information into safer medication use.^1-3

REFERENCES

1. Adams B. Naox Technologies nabs 1st FDA clearance for in-ear EEG brain monitoring device. Fierce Biotech. January 6, 2026. Accessed January 12, 2026. https://www.fiercebiotech.com/medtech/naox-technologies-nabs-first-ever-fda-clearance-ear-eeg-brain-monitoring-device

2. George J. First in-ear EEG device gets FDA clearance. MedPage Today. January 6, 2026. Accessed January 12, 2026. https://www.medpagetoday.com/neurology/generalneurology/119305

3. Buntz B. How EEG data and machine learning can inform drug development. Drug Discovery and Development. July 22, 2022. Accessed January 12, 2026. https://www.drugdiscoverytrends.com/how-eeg-data-and-machine-learning-can-inform-drug-development/